Allogene Therapeutics
General information
Main focus: Allogeneic CAR-T cell therapies
Company stage: Clinical
Diseases: Non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), acute myeloid leukaemia (AML), renal cell carcinoma (RCC), small cell lung cancer (SCLC)
Genome editing tool: TALEN
Funding stage: Public (NASDAQ:ALLO)
Location: San Francisco, CA, USA
Website: http://allogene.com/
Pipeline: https://www.allogene.com/pipeline
Partners: Cellectis, Servier, Notch Therapeutics, SpringWorks Therapeutics, Pfizer
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Allogene is developing a pipeline of off-the-shelf CAR-T cell therapy candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.